CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Saline solutionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1169 IgG Wiki 0.71
drug1910 Probiorinse Wiki 0.71
drug1978 Questionnaire Wiki 0.29
drug647 Convalescent Plasma Wiki 0.15

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

NCT04364737 COVID-19 Coronavirus Coronavirus Infection Biological: Convalescent Plasma Other: Saline solution
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Uninfected 0 Uninfected; no viral RNA detected Ambulatory 1 Asymptomatic; viral RNA detected 2 Symptomatic; Independent 3 Symptomatic; assistance needed Hospitalized: Mild disease 4 Hospitalized; no oxygen therapy 5 Hospitalized; oxygen by mask or nasal prongs Hospitalized: Severe disease 6 Hospitalized; oxygen by NIV or High flow 7 Intubation & Mechanical ventilation; pO2/FIO2 >/= 150 or SpO2/FIO2 >/=200 8 Mechanical ventilation pO2/FIO2 < 150 (SpO2/FIO2 <200) or vasopressors 9 Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis or ECMO Death 10 Dead

Measure: Score on the WHO 11-point ordinal scale for clinical improvement at 14 days

Time: 14 days post randomization

Secondary Outcomes

Description: Uninfected 0 Uninfected; no viral RNA detected Ambulatory 1 Asymptomatic; viral RNA detected 2 Symptomatic; Independent 3 Symptomatic; assistance needed Hospitalized: Mild disease 4 Hospitalized; no oxygen therapy 5 Hospitalized; oxygen by mask or nasal prongs Hospitalized: Severe disease 6 Hospitalized; oxygen by NIV or High flow 7 Intubation & Mechanical ventilation; pO2/FIO2 >/= 150 or SpO2/FIO2 >/=200 8 Mechanical ventilation pO2/FIO2 < 150 (SpO2/FIO2 <200) or vasopressors 9 Mechanical ventilation pO2/FIO2 < 150 and vasopressors, dialysis or ECMO Death 10 Dead

Measure: Score on the WHO 11-point ordinal scale for clinical improvement at 28 days

Time: 28 days post randomization

Other Outcomes

Description: Anti-SARS-CoV-2 titers (IgM, IgG, IgA)

Measure: Comparison in Anti-SARS-CoV-2 antibody titers

Time: 0, 1, 7, 14, 28, 90 days post randomization

Description: SARS-CoV-2 PCR in nasopharyngeal swabs

Measure: Proportion positive in SARS-CoV-2 RNA

Time: 0, 7, 14, 28 days post randomization

Description: Rate of mortality

Measure: Mortality

Time: 7, 14, 28 days post randomization

Description: Percentage of patients requiring Intensive Care Unit admission

Measure: Rates of Intensive Care Unit admission

Time: 7, 14, 28 days post randomization

Description: Lymphocyte counts

Measure: Changes from baseline in lymphocyte

Time: 0, 1, 3, 7, 14 days post randomization

Description: Neutrophil counts

Measure: Changes from baseline in neutrophils

Time: 0, 1, 3, 7, 14 days post randomization

Description: D-dimer level

Measure: Changes from baseline in D-dimer

Time: 0, 1, 3, 7, 14 days post randomization

Description: Fibrinogen level

Measure: Changes from baseline in fibrinogen

Time: 0, 1, 3, 7, 14 days post randomization

Description: T cell subsets

Measure: Changes from baseline in T lymphocyte subsets

Time: 0, 7, 28 days post randomization

Description: B cell subsets

Measure: Changes from baseline in B lymphocyte subsets

Time: 0, 1, 3, 7, 14 days post randomization

2 Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection

Randomised, single-blinded trial. Patients with a diagnosis of COVID-19 infection within the past 96 hours and not requiring hospitalization will be recruited into a trial of BID Nasal irrigation for 14 days, followed by a 14 day observation period. Irrigation will be performed with either Probiorinse probiotic nasal irrigation solution or NeilMed Sinus rinse. Patients will be able to identify their treatments, but study staff will be blinded as to assignment.

NCT04458519 COVID-19 Infection Other: Probiorinse Other: Saline solution
MeSH:Infection Communicable Diseases

Primary Outcomes

Description: Change in severity of COVID-19 infection as assessed by number of days with any symptoms of COVID-19 infection greater than or equal to 35 as measured on VAS scale as assessed at the 28 day endpoint.

Measure: Change in severity of COVID-19 infection

Time: 4 weeks

Secondary Outcomes

Description: Number of days with any symptom of anosmia

Measure: Number of days with any symptom of anosmia

Time: 4 weeks

Description: Maximal intensity attained in overall assessment of symptoms of COVID-19 infection as measured on Visual Analogue Scale (VAS). VAS scale from 0 to 100, with a higher score indicating a worse outcome.

Measure: Maximal intensity attained in overall assessment of symptoms of COVID-19 infection as measured on Visual Analogue Scale (VAS).

Time: 4 weeks

Description: Number of days where rescue medication is required

Measure: Number of days where rescue medication is required

Time: 4 weeks

No related HPO nodes (Using clinical trials)